Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis

347 Followers

RARE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$33.36 - $85.53
Previous Close$43.72
Volume449.66K
Average Volume (3M)761.20K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$888.67M
Total Debt (Recent Filing)$34.68M
Price to Earnings (P/E)-4.5
Beta-0.93
Next EarningsFeb 16, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-9.74
Shares Outstanding70,105,654
R-Squared0.11
Standard Deviation0.16
10 Day Avg. Volume752,646
30 Day Avg. Volume761,196
Price to Book (P/B)10.94
Price to Sales (P/S)11.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside105.67% Upside
Rating ConsensusStrong Buy
Alpha0.00525
Number of Analyst Covering12


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

RARE FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $33.36 and its highest was $85.53 in the past 12 months.
    What is Ultragenyx Pharmaceutical’s market cap?
    Currently, no data Available
    When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
    Ultragenyx Pharmaceutical’s upcoming earnings report date is Feb 16, 2023 which is in 17 days.
      How were Ultragenyx Pharmaceutical’s earnings last quarter?
      Ultragenyx Pharmaceutical released its earnings results on Nov 02, 2022. The company reported -$3.5 earnings per share for the quarter, missing the consensus estimate of -$1.811 by -$1.689.
        Is Ultragenyx Pharmaceutical overvalued?
        According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Ultragenyx Pharmaceutical pay dividends?
          Ultragenyx Pharmaceutical does not currently pay dividends.
          What is Ultragenyx Pharmaceutical’s EPS estimate?
          Ultragenyx Pharmaceutical’s EPS estimate is -$2.14.
            How many shares outstanding does Ultragenyx Pharmaceutical have?
            Ultragenyx Pharmaceutical has 70,105,650 shares outstanding.
              What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
              Ultragenyx Pharmaceutical reported an EPS of -$3.5 in its last earnings report, missing expectations of -$1.811. Following the earnings report the stock price went down -5.962%.
                Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
                Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Echo Street Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 650K.

                  ---

                  Ultragenyx Pharmaceutical Stock Smart Score

                  8
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  The Ultragenyx Pharmaceutical stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Ultragenyx Pharmaceutical

                  Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Arrowhead Pharmaceuticals
                  Beam Therapeutics
                  PTC Therapeutics
                  Blueprint Medicines
                  IVERIC bio

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis